News - EN

Candida auris

2025-10-07 10:39
  1. Efficient prevention of drug-resistant Candida auris
  2. Disinfection as a key measure to prevent infections
  3. Also effective with short contact times
Cologne, 17 May 2023 – The broad-spectrum disinfectant Rely+On Virkon, produced by the specialty chemicals company LANXESS, has demonstrated its efficacy against the yeast Candida auris. This makes it suitable for use as a disinfectant in healthcare and institutional facilities where an infection by this drug-resistant yeast has been detected or suspected, or where prevention is desired from the outset.

The disinfectant is effective even with short contact times (0.75 % in 5 minutes according to EN 1650 standard) and enables disinfection and decontamination of hard surfaces. It is also suitable for laboratory applications.

Anneliese Bischof, Head of the CARE Business Line within the Material Protection Products unit at LANXESS, states:
“Practising good hygiene must always be part of our daily routine, but choosing a disinfectant proven to eliminate major pathogens is essential.”
As cases of drug-resistant pathogens continue to cause serious concern in healthcare facilities worldwide, governmental health departments provide advice and guidance on how to better prevent transmission through hygiene and disinfection practices, which remain of utmost importance.

According to the US CDC, 90 % of Candida auris isolates are resistant to at least one antifungal drug, and 30 % of them are resistant to at least two antifungal agents.
“Therefore, using Rely+On Virkon as a surface disinfectant to control infections can help disinfect areas at high risk of Candida auris transmission, thereby reducing the infection risk for patients, medical and laboratory staff,” concludes Bischof.